公开(公告)号：US20220033462A1

公开(公告)日：2022-02-03

申请号：US17385805

申请日：2021-07-26

Applicant: ALLOGENE THERAPEUTICS, INC. ,  CELLECTIS

Inventor： ARVIND RAJPAL ,  Shobha Chowdary Potluri ,  Laurent Poirot ,  Alexandre Juillerat ,  Thomas Charles Pertel ,  Donna Marie Stone ,  Barbra Johnson Sasu

IPC: C07K14/705 ,  C07K16/30 ,  A61K35/17 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783

Abstract: The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V or I.

公开(公告)号：US11072644B2

公开(公告)日：2021-07-27

申请号：US15525906

申请日：2015-11-09

Applicant: ALLOGENE THERAPEUTICS, INC. ,  CELLECTIS

Inventor： Arvind Rajpal ,  Shobha Chowdary Potluri ,  Laurent Poirot ,  Alexandre Juillerat ,  Thomas Charles Pertel ,  Donna Marie Stone ,  Barbra Johnson Sasu

IPC: C07K14/705 ,  C07K16/30 ,  A61K35/17 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783 ,  A61K39/00

Abstract: The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V or I.

公开(公告)号：US12209125B2

公开(公告)日：2025-01-28

申请号：US16755082

申请日：2018-03-09

Applicant: CELLECTIS

Inventor： Brian Busser ,  Philippe Duchateau ,  Alexandre Juillerat ,  Laurent Poirot ,  Julien Valton

IPC: A61K35/00 ,  A61K39/00 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N5/10

Abstract: The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.

公开(公告)号：US11365430B2

公开(公告)日：2022-06-21

申请号：US16793918

申请日：2020-02-18

Applicant: Cellectis

Inventor： Philippe Duchateau ,  André Choulika ,  Laurent Poirot

IPC: A61K35/17 ,  C12N15/85 ,  C12N5/0783 ,  C12N9/22 ,  C12N15/90 ,  C12N15/113

Abstract: The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.

公开(公告)号：US10426795B2

公开(公告)日：2019-10-01

申请号：US14403937

申请日：2013-05-13

Applicant: Cellectis

Inventor： Roman Galetto ,  Agnes Gouble ,  Stephanie Grosse ,  Cecile Mannioui ,  Laurent Poirot ,  Andrew Scharenberg ,  Julianne Smith

IPC: C12N5/10 ,  A61K38/00 ,  A61K35/17 ,  C12N5/0783 ,  C07K14/725 ,  C07K16/28 ,  C07K14/705

Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US10196608B2

公开(公告)日：2019-02-05

申请号：US15120060

申请日：2015-02-20

Applicant: CELLECTIS

Inventor： Laurent Poirot ,  Philippe Duchateau

IPC: C12N9/16 ,  A61K35/17 ,  C07K14/47 ,  C07K16/28 ,  C07K14/715 ,  C07K14/725 ,  C12N5/0783

Abstract: The present invention pertains to engineered T-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered T-cells of the invention are designed to express both a Chimeric Antigen Receptor (CAR) directed against at least one antigen expressed at the surface of a malignant or infected cell, and a secreted inhibitor of regulatory T-cells (Treg). Preferably, such secreted inhibitor is a peptide inhibitor of forkhead/winged helix transcription factor 3 (FoxP3), a specific factor involved into the differentiation of T-cells into regulatory T-cells. The engineered T-cells of the invention direct their immune activity towards specific malignant or infected cells, while at the same time will prevent neighboring regulatory T-cells from modulating the immune response. The invention opens the way to standard and affordable adoptive immunotherapy strategies, especially for treating or preventing cancer, and bacterial or viral infections.

公开(公告)号：US12144825B2

公开(公告)日：2024-11-19

申请号：US16625678

申请日：2018-07-02

Applicant: CELLECTIS

Inventor： David Sourdive ,  Aymeric Duclert ,  Mathieu Simon ,  Philippe Duchateau ,  Alan Marc Williams ,  Laurent Poirot

IPC: A61K35/17 ,  A61K39/00 ,  C12Q1/6881

Abstract: The present invention provides composition kits and methods for treating cancer in a human by immunotherapy using successive doses of CAR-T cells with no or reduced anamnestic immune reaction in one individual (P).

公开(公告)号：US11414674B2

公开(公告)日：2022-08-16

申请号：US16361438

申请日：2019-03-22

Applicant: Cellectis

Inventor： Roman Galetto ,  Agnes Gouble ,  Stephanie Grosse ,  Cecile Mannioui ,  Laurent Poirot ,  Andrew Scharenberg ,  Julianne Smith

IPC: A61K35/17 ,  C12N15/85 ,  C07K14/705 ,  C12N5/0783 ,  C07K14/725 ,  C07K16/28 ,  A61K39/00 ,  A61K38/00

Abstract: A method of expanding deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US10517896B2

公开(公告)日：2019-12-31

申请号：US16361370

申请日：2019-03-22

Applicant: Cellectis

Inventor： Roman Galetto ,  Agnes Gouble ,  Stephanie Grosse ,  Cecile Mannioui ,  Laurent Poirot ,  Andrew Scharenberg ,  Julianne Smith

IPC: A61K35/26 ,  A61K35/17 ,  C07K14/705 ,  C12N5/0783 ,  C07K14/725 ,  C07K16/28 ,  A61K38/00

Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US10472613B2

公开(公告)日：2019-11-12

申请号：US15517708

申请日：2015-10-07

Applicant: CELLECTIS

Inventor： Philippe Duchateau ,  Alexandre Juillerat ,  Laurent Poirot

IPC: C07K14/705 ,  C12N5/16 ,  C07K14/725 ,  C12N5/078 ,  C12N5/0783 ,  C12N5/10 ,  C12N5/07 ,  C12N15/02 ,  C12N15/87

Abstract: The present invention relates to a method to modulate the level of activation of an engineered immune cell (such as a Chimeric Antigen Receptor T-cell) for immunotherapy. The present invention also relates to cells obtained by the present method, preferably comprising said modulable/tunable chimeric antigen receptors for use in therapeutic or prophylactic treatment.